Cantor’s Elemer Piros waits for pass-through reimbursement to be address, before joining the ‘Omeros party’.
Brexanolone poised to become first approved therapy for PPD, says Needham’s Danielle Brill.
The market has divided itself into two camps. The bulls argue that the worst is …
Is Valeant on track to overcome financial troubles? Mizuho’s Irina Rivkind Koffler remains unconvinced.
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) tumbled nearly 9% in Monday’s trading session, after the …
TX-004 is on the path to FDA approval; Cantor’s William Tanner Sees 450% Upside.
MannKind’s capital raise is not enough, says Jason Kolbert.
Eric Schmidt views BIIB shares as undervalued based upon a stable MS franchise and Spinraza’s potential.
Healthcare analysts take different approaches to valuing Transenterix and Valeant.
ROS1-Positive interim data raises Mara Goldstein’s conviction.